Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 3/20 | 0.67 |
| ▸ | MMP9 | P14780 | 3/20 | 0.67 |
| ▸ | MMP8 | P22894 | 3/20 | 0.67 |
| ▸ | MMP13 | P45452 | 3/20 | 0.67 |
| ▸ | NPC1 | O15118 | 2/20 | 0.60 |
| ▸ | RAB9A | P51151 | 2/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.60 |
| ▸ | MAPT | P10636 | 2/20 | 0.60 |
| ▸ | AGPAT2 | O15120 | 11/20 | 0.58 |
| ▸ | PPARG | P37231 | 2/20 | 0.54 |
| ▸ | PTGES | O14684 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4505279 | 0.88 | MAPT (0.58) | MMP2MMP9MMP8MMP13NPC1 | |
| SCHEMBL4513561 | 0.85 | MAPT (0.60) | MMP2MMP9MMP8MMP13NPC1 | |
| SCHEMBL5834798 | 0.85 | MMP2 (0.67) | MMP2MMP9MMP8MMP13NPC1 | |
| SCHEMBL4514389 | 0.85 | RAB9A (0.50) | MMP2MMP9MMP8MMP13NPC1 | |
| SCHEMBL2690401 | 0.84 | MMP2 (0.63) | MMP2MMP9MMP8MMP13NPC1 | |
| SCHEMBL4511714 | 0.83 | MMP2 (0.65) | MMP2MMP9MMP8MMP13NPC1 | |
| SCHEMBL2244223 | 0.81 | MMP2 (1.00) | MMP2MMP9MMP8MMP13NPC1 | |
| SCHEMBL4513288 | 0.80 | APEX1 (0.59) | MMP2MMP9MMP8MMP13NPC1 | |
| SCHEMBL4504507 | 0.80 | MMP2 (0.60) | MMP2MMP9MMP8MMP13NPC1 | |
| SCHEMBL5834465 | 0.79 | MMP2 (0.58) | MMP2MMP9MMP8MMP13NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090258917-A1 | Benzoxazoles Useful in the Treatment of Inflammation | BIOLIPOX AB (SE) | 2009-10-15 | — | — | US | disclosed |
| EP-1933834-A1 | BENZOXAZOLES USEFUL IN THE TREATMENT OF INFLAMMATION | Biolipox AB (SE) | 2008-06-25 | — | — | EP | disclosed |
| WO-2007042816-A1 | BENZOXAZOLES USEFUL IN THE TREATMENT OF INFLAMMATION | BIOLIPOX AB (SE) | 2007-04-19 | — | — | WO | disclosed |
| WO-2002036580-A9 | BENZOXAZOLE LPAAT- BETA INHIBITORS AND USES THEREOF | BONHAM LYNN (US) | 2003-02-13 | — | — | WO | disclosed |
| US-20020107269-A1 | Benzoxazole LPAAT-B inhibitors and uses thereof | CELL THERAPEUTICS, INC. | 2002-08-08 | — | — | US | disclosed |
| WO-2002036580-A2 | BENZOXAZOLE LPAAT- BETA INHIBITORS AND USES THEREOF | BONHAM LYNN (US) | 2002-05-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020107269-A1 | Benzoxazole LPAAT-B inhibitors and uses thereof | LPCAT3, LPCAT1, PLAAT2 | MMP2 1513/4885MMP9 809/4885MMP8 1466/4885 |
| US-20090258917-A1 | Benzoxazoles Useful in the Treatment of Inflammation | IL4I1, EPX, IL4 | MMP2 181/4885MMP9 466/4885MMP8 53/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.